SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that five abstracts, including one late-breaker, highlighting data from its Cloudbreak® antiviral program have been accepted for presentation at the Options X for the Control of Influenza conference taking place August 28-September 1 in Singapore.
“Cidara’s presentations at this important global conference highlight our commitment to addressing an unmet medical need for better and more effective approaches to fighting influenza,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “The data we’ve generated in animal models demonstrate the potential of our antiviral conjugates, known as AVCs, in treating and preventing infections caused by a broad array of seasonal and pandemic strains of influenza. A single AVC molecule, which links a potent antiviral drug with a long-acting immune system engager, has the potential for important advantages over traditional vaccines and therapies.”
Options X is the largest international conference exclusively dedicated to influenza prevention, control and treatment, including seasonal flu and pandemic preparedness, and the premier event of the International Society of Influenza and other Respiratory Virus Diseases (ISIRV). Cidara’s presentations will feature data from preclinical studies evaluating the antiviral activity of CB-012, the first AVC candidate generated by its Cloudbreak anti-infective immunotherapy platform, against seasonal and pandemic influenza A and influenza B strains.
Details of Cidara’s poster presentations are as follows:
Late-Breaker Presentation
Title: Efficacy of CB-012, A Novel Antiviral Fc-Conjugate, against Influenza A (H1N1) In a Lethal Mouse Model of Severe Combined Immunodeficiency (SCID)
Abstract ID: 11760
Presenter: L. Tari
Date and time: Wednesday, August 28 from 6:30 p.m. – 7:30 p.m. Singapore Time
Location: Exhibition Hall, Hall 404, Level 4, Suntec Singapore Convention & Exhibition Centre
Session Topic: Clinical Sciences: Therapeutics-Antivirals
Poster Presentations
Title: Efficacy of CB-012, A Novel Antiviral Fc-Conjugate, in Lethal Mouse Models of Oseltamivir-Sensitive and -Resistant Influenza A H1N1 and H3N2 Isolates
Abstract ID: 10979
Presenter: J. Levin
Date and time: Friday, August 30 from 6:00 p.m. – 7:30 p.m. Singapore Time
Location: Exhibition Hall, Hall 404, Level 4, Suntec Singapore Convention & Exhibition Centre
Session Topic: Virology and Pathogenesis: Viral Replication
Title: Fc-Mediated Effector Function Contributes to Potency of Novel Antiviral Fc-Conjugate CB-012
Abstract ID: 11094
Presenter: S. Döhrmann
Date and time: Friday, August 30 from 6:00 p.m. – 7:30 p.m. Singapore Time
Location: Exhibition Hall, Hall 404, Level 4, Suntec Singapore Convention & Exhibition Centre
Session Topic: Virology and Pathogenesis: Viral Replication
Title: Novel Antiviral Fc-Conjugate CB-012 Demonstrates Potent Activity in Cytopathic Effect (CPE) and Viral Growth Inhibition Assays against Influenza A and B Strains
Abstract ID: 10974
Presenter: J. Locke
Date and time: Friday, August 30 from 6:00 p.m. – 7:30 p.m. Singapore Time
Location: Exhibition Hall, Hall 404, Level 4, Suntec Singapore Convention & Exhibition Centre
Session Topic: Virology and Pathogenesis: Viral Replication
Title: Preclinical Efficacy, Pharmacokinetics, and Safety of CB-012, A Novel Antiviral Fc-Conjugate against Influenza
Abstract ID: 10973
Presenter: V. Ong
Date and time: Friday, August 30 from 6:00 p.m. – 7:30 p.m. Singapore Time
Location: Exhibition Hall, Hall 404, Level 4, Suntec Singapore Convention & Exhibition Centre
Session Topic: Virology and Pathogenesis: Viral Replication
Following the meeting, the presentation slides and posters will be available on the Cidara website: www.cidara.com.
About Cloudbreak AVCs
Cidara’s Cloudbreak AVCs are potent, small-molecule antivirals conjugated to the Fc domain of a human antibody (IgG1). This design allows AVCs to work in multiple ways. In addition to directly targeting and inhibiting viral replication, AVCs focus the immune system on the infection, similar to how certain cancer immunotherapies engage the immune system to destroy cancer cells. With this novel approach, Cidara believes its AVCs have the potential to protect for an entire flu season with a single dose, with or without concurrent vaccination, and to provide a highly potent treatment for seasonal and pandemic influenza.
About Influenza
Influenza, or flu, is a respiratory infection caused by influenza viruses. The flu virus can cause mild to severe illness and, at times, can lead to death. Young children, the elderly (people aged 65 years and older), pregnant women and immunocompromised patients are more prone to infection, but even healthy people are at risk of infection with seasonal flu. While influenza vaccines are critical to global health, they have limited efficacy and must be redesigned every year based on a prediction of the next season’s dominant circulating strains.
On average, vaccines are only 40 percent effective, with lower rates in young children and the elderly. The U.S. Centers for Disease Control and Prevention (CDC) estimates that as many as 646,000 people may die from influenza each year worldwide. According to CDC estimates for the United States, approximately 50 million people became ill from the flu and almost 80,000 people died in the 2017-18 season alone.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE). A second Phase 3 trial of once-weekly rezafungin for prophylaxis against invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation (ReSPECT) is planned pending adequate funding and approval from the relevant regulatory authorities. In addition to its robust rezafungin clinical program, Cidara is applying its proprietary Cloudbreak® platform to develop antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases. The Cloudbreak platform is designed to discover compounds that both directly kill pathogens and direct a patient’s immune system to attack and eliminate pathogens. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Cidara’s ability to develop new anti-infectives that are innovative or address unmet needs, and the potential for rezafungin to successfully treat or prevent invasive fungal infections and represent an improvement over current approaches and Cidara’s ability to successfully develop rezafungin, the potential for Cloudbreak AVCs to treat and prevent influenza caused by a broad array of strains and represent an improvement over current vaccines, and the ability of Cidara’s AVCs to provide protection for an entire flu season with a single dose. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-K most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190821005149/en/
INVESTOR CONTACT:
Robert H. Uhl
Westwicke Partners, LLC
Managing Director
(858) 356-5932
robert.uhl@westwicke.com
MEDIA CONTACT:
Andrea Cohen
Sam Brown Inc.
(917) 209-7163
andreacohen@sambrown.com
